WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510331
Description: TAK-063, also known as Balipodect., is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.
MedKoo Cat#: 510331
Chemical Formula: C23H17FN6O2
Exact Mass: 428.1397
Molecular Weight: 428.42
Elemental Analysis: C, 64.48; H, 4.00; F, 4.43; N, 19.62; O, 7.47
TAK-063 (Balipodect), purity > 98%, is in stock. The same day shipping out after order is received.
Synonym: TAK063, TAK 063, TAK-063, Balipodect
IUPAC/Chemical Name: 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one
InChi Key: KVHRYLNQDWXAGI-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3
SMILES Code: O=C1C(C2=CC=NN2C3=CC=CC=C3)=NN(C4=CC=C(N5N=CC=C5)C=C4F)C=C1OC
The following data is based on the product molecular weight 428.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Suzuki K, Harada A, Shiraishi E, Kimura H. In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents. J Pharmacol Exp Ther. 2015 Mar;352(3):471-9. doi: 10.1124/jpet.114.218552. Epub 2014 Dec 18. PubMed PMID: 25525190.
2: Kunitomo J, Yoshikawa M, Fushimi M, Kawada A, Quinn JF, Oki H, Kokubo H, Kondo M, Nakashima K, Kamiguchi N, Suzuki K, Kimura H, Taniguchi T. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyri dazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem. 2014 Nov 26;57(22):9627-43. doi: 10.1021/jm5013648. Epub 2014 Nov 10. PubMed PMID: 25384088.